Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company is transitioning from automotive manufacturing to AI technology, with significant growth expected in revenue and profit margins by 2026 [1][8] - The company plans to launch seven new models in 2026, focusing on both pure electric and extended-range vehicles, while expanding its global presence [8][41] - The Robotaxi segment is anticipated to reshape the Chinese transportation market, with commercial operations expected to accelerate in 2026 [8][50] Summary by Sections C-end Smart Vehicles - The company aims to build a "mass production capability" for multiple successful vehicle models, leveraging a platform-based technology approach [14][15] - The introduction of the X9 EREV model highlights the company's focus on long-range capabilities and efficient energy consumption [23][30] - The company has achieved significant growth in monthly deliveries, indicating a successful product strategy [20][41] B-end Robotaxi - The company is positioned to benefit from favorable policies and technological advancements in the Robotaxi market, with expectations for commercial operations to begin in 2026 [50] - The Robotaxi project is expected to leverage the company's AI capabilities and innovative business models to capture market share [8][50] Collaboration with Volkswagen - The partnership with Volkswagen has evolved from joint vehicle development to deeper collaboration on electronic architecture and AI technology [8][24] - The collaboration is expected to enhance the company's market position as a provider of intelligent technology solutions [8][24] Robotics and Flying Cars - The company is advancing its robotics initiatives, with plans for commercial applications of its IRON robot in various service scenarios by 2026 [8][24] - The flying car project is nearing production, with successful test flights and significant pre-orders indicating strong market interest [8][24]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 0.79 [2][6]. Core Insights - The company reported a revenue of RMB 3.96 billion for FY25, representing a year-on-year growth of 6.1%, while net profit decreased by 36.9% to RMB 390 million. Adjusted net profit, excluding certain impairments, increased by 6.5% to RMB 740 million, aligning with expectations [3][4]. - The company has optimized its school count and strengthened headquarters management, which is expected to lead to a recovery in profit margins. The average tuition fee increased by 6% to RMB 13,600 per academic year [4][6]. - The company sold eight low-efficiency school assets from FY24 to FY25, aiming to enhance operational efficiency by reducing the number of schools and increasing the proportion of undergraduate students [5][6]. Financial Data and Profit Forecast - For FY25, the company’s revenue is projected at RMB 3.96 billion, with an adjusted net profit of RMB 738 million. The adjusted net profit is expected to grow to RMB 764 million in FY26 and RMB 812 million in FY27 [7][10]. - The gross margin for FY25 is reported at 42.1%, slightly lower than the previous year, but operational efficiency is anticipated to improve moving forward [4][6]. - The company’s student enrollment for FY25 is 291,000, with a stable student structure, where undergraduate students account for 48% and vocational students for 3% [4][5].

Investment Rating - The report assigns a "Buy" investment rating to the company [2] Core Views - The report highlights that the company is undergoing a significant improvement in profitability, with a notable 17% year-on-year growth in net profit for Q3 2025, driven by a reduction in sales and management expense ratios [5][27] - The company is expected to benefit from the ongoing consolidation in the pharmaceutical distribution industry, with its market share increasing to 20.36% in 2023 [5][44] - The report emphasizes the company's commitment to enhancing operational quality and optimizing its business structure, which is anticipated to lead to sustained profit growth in 2026 [5][15] Summary by Sections Company Overview - The company, China National Pharmaceutical Group Corporation (Sinopharm), is a leading player in the pharmaceutical distribution industry, with a comprehensive business layout that includes pharmaceutical distribution, medical device distribution, and retail [17][18] - The company has achieved a compound annual growth rate (CAGR) of approximately 9% in revenue over the past seven years, with a significant 17% growth in net profit for Q3 2025 [22][27] Industry Dynamics - The pharmaceutical distribution industry has seen an increase in concentration, with the market share of the top four companies rising from 38.38% in 2019 to 42.69% in 2023 [13][43] - The report notes that the company's pharmaceutical distribution revenue is projected to grow at a CAGR of about 7% from 2018 to 2024, with a focus on high-demand and high-value products [5][36] Financial Performance - The company reported total revenue of approximately 584.5 billion yuan in 2024, with a projected revenue of 577.2 billion yuan for 2025, reflecting a slight decline of 1% [6][27] - The net profit attributable to the parent company is expected to reach 80.77 billion yuan in 2025, representing a 15% increase year-on-year [6][27] Dividend Policy - The company has steadily increased its dividend payout ratio from 28.1% in 2021 to 30.98% in 2024, with an average dividend yield of 4.45% over the past five years [5][16] - The report indicates that the company's price-to-book (PB) ratio is currently around 0.71, which is below the five-year average of 0.81, suggesting potential for valuation improvement [5][16]

Investment Rating - The report maintains a "Buy" rating and adjusts the target price to HKD 0.73 [3][5] Core Insights - The company has shown impressive market expansion results, with a significant reduction in related party impairment risks [2] - The company is focusing on core city clusters and high-energy markets, with 74% of new projects located in key regions [10] - The company has reduced the annual cap on related party transactions, which helps lower the risk of receivable impairments and strengthens its independence [10] Financial Performance Summary - Revenue projections for 2025 and 2026 have been adjusted to HKD 7,249 million and HKD 7,571 million, respectively, with a forecasted EPS of HKD 0.02 and HKD 0.06 [3][9] - The company reported a net profit of HKD 273 million in 2023, with a projected net profit of HKD 59 million in 2025 and HKD 145 million in 2026 [9][12] - The gross margin is expected to decline from 20.1% in 2023 to 17.5% by 2027 [9][12] Market Expansion and Strategy - The company achieved a record high in third-party bidding, with an annual contract amount of approximately HKD 960 million, a year-on-year increase of 54.6% [10] - The average property management fee for new residential projects reached HKD 2.9 per square meter per month, indicating improved project quality and profitability [10] - The company added nearly 200 new projects in the second half of the year, expanding its service scenarios and customer value boundaries [10]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - The company reported a revenue of HKD 34.48 billion for the first half of the 2025/26 fiscal year, a decrease of 1.8% year-on-year. The net profit attributable to shareholders was HKD 1.334 billion, down 24.2% year-on-year. Free cash flow reached HKD 2.6 billion, an increase of approximately 17% year-on-year. The interim dividend per share remained unchanged at HKD 0.15 [2][4]. Summary by Sections Revenue and Profitability - The total gas sales volume increased by 1.7%, with natural gas sales revenue at HKD 20.38 billion, up 3.8% year-on-year. However, engineering design and installation revenue decreased by 5.2% to HKD 3.16 billion, and liquefied petroleum gas sales revenue fell by 12.3% to HKD 8.38 billion [7]. - The average procurement price for gas was HKD 2.63 per cubic meter, unchanged year-on-year, while the average gross margin was HKD 0.58 per cubic meter, a slight decrease of HKD 0.01 year-on-year [7]. Customer Pricing and Sales - As of September 2025, the cumulative proportion of residential gas price adjustments reached approximately 74%, with residential gas prices increasing from HKD 2.56 per cubic meter in the 2021/22 fiscal year to HKD 2.87 per cubic meter in the 2025/26 fiscal year [7]. - The average industrial customer gas price was HKD 3.28 per cubic meter, slightly down by HKD 0.02 year-on-year, while the commercial customer gas price was HKD 3.49 per cubic meter, a slight increase of HKD 0.03 year-on-year [7]. Cash Flow and Dividends - The company achieved a free cash flow of HKD 2.6 billion, reflecting a year-on-year increase of approximately 17%. The expected annual dividend per share is maintained at HKD 0.50, resulting in a current dividend yield of approximately 5.84% [7]. - The financing cost has decreased, with the average financing cost dropping from 3.84% in the previous fiscal year to 3.39% [7]. Customer Connections - The company added approximately 676,300 new residential connections in the first half of the fiscal year, a decrease of 25.2% year-on-year. The full-year guidance for new connections remains unchanged at 1 to 1.2 million [7]. - The performance contribution from connection and engineering segments has decreased to 16.0% [7]. Value-Added Services - The value-added services segment generated approximately HKD 1.015 billion in revenue, accounting for 30.0% of total revenue, with a year-on-year increase of 1.3% [7].

Investment Rating - The investment rating for the company is maintained as "Buy" [2] Core Views - The company reported a revenue of 3.96 billion RMB for the fiscal year 2025, representing a year-on-year growth of 6.1%. However, net profit decreased by 36.9% to 390 million RMB. Adjusted net profit, excluding goodwill impairment and convertible bond disposal costs, was 740 million RMB, reflecting a growth of 6.5% [5] - The company has optimized its school count and strengthened headquarters management, which is expected to lead to a recovery in profit margins. The number of enrolled students remained stable at 291,000, with a slight increase of 0.1% compared to the previous fiscal year [5][6] - The average tuition fee increased by 6% to 13,600 RMB per academic year. The company effectively controlled cost growth, with main operating costs rising by 6.2% to 2.29 billion RMB, slightly above the revenue growth rate [5][6] Financial Data and Profit Forecast - The company expects adjusted profits for fiscal year 2026 to be 760 million RMB, down from an earlier forecast of 1.27 billion RMB. Adjusted profits for fiscal years 2027 and 2028 are projected to be 810 million RMB and 880 million RMB, respectively [7][8] - The financial data shows a steady increase in revenue and adjusted net profit over the forecast period, with revenue expected to reach 4.55 billion RMB by fiscal year 2028 [8][11]

Investment Rating - The report gives a "Buy" rating for the company, 康哲药业 (0867.HK), for the first time [7]. Core Views - The company has successfully transitioned into a new product era, with its innovative transformation showing significant results. The impact of national procurement on its products has reached a turning point, and the sales of exclusive/brand and innovative products continue to grow, indicating a recovery in performance [7]. - The company is focusing on dual engines of "cooperative research and independent research" to drive innovation, with a rich product pipeline covering multiple therapeutic areas. The company aims to enhance its market position through strategic international expansion and innovative product launches [6][10]. Summary by Sections 1. Successful Innovation Transformation - The company has adopted a dual approach of "cooperative research + independent research" to efficiently promote clinical development and commercialization. It has transitioned from a single drug agency model to an innovation-driven pharmaceutical enterprise since 2018 [10]. - As of the first half of 2025, the company has a pipeline of 40 products, with five innovative products approved for sale in China [10]. 2. Impact of National Procurement - The company faced a decline in revenue and net profit in 2023 due to three products being included in national procurement, leading to a significant drop in sales and market share [12]. - In 2025, the company’s performance rebounded, achieving revenue of 40.02 billion yuan (up 10.8% year-on-year) and a net profit of 9.41 billion yuan (up 3.3% year-on-year) [12]. 3. Innovative Drug Strategy - The company has successfully launched four innovative drugs, with a focus on chronic kidney disease, psoriasis, and epilepsy. Two additional products are pending approval, and three are in clinical phase III trials [34][36]. - The company’s innovative pipeline includes products targeting skin health, with plans for a spin-off of 德镁医药 to unlock its value in the skin health sector [21][34]. 4. Financial Forecast and Valuation - The company is expected to achieve net profits of 16.70 billion yuan, 20.05 billion yuan, and 23.72 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 18, 15, and 12 times [7]. - The company’s P/E valuation for 2025 is estimated at 18 times, which is lower than the average P/E of comparable companies at 28 times [7].

Investment Rating - The investment rating for Geely Automobile is "Buy" and is maintained [6]. Core Views - Geely Automobile reported a total sales volume of 310,000 units in November 2025, representing a year-on-year increase of 24.1% and a month-on-month increase of 1.1%. Cumulatively, from January to November 2025, total sales reached 2.788 million units, up 41.8% year-on-year. The new platform is expected to empower Geely to enter a new product era [2][4][7]. - The GEA architecture supports a new vehicle cycle, with positive developments across the Zeekr, Lynk & Co, and Galaxy brands. The transition to new energy vehicles is progressing smoothly, and the scale effect is expected to enhance profitability. The company maintains a solid foundation in fuel vehicles, and joint ventures are exploring innovative overseas expansion models. The smart driving strategy is set to accelerate the enhancement of intelligent driving capabilities, indicating significant profitability elasticity in the new vehicle cycle [2][7]. Summary by Sections Sales Performance - In November 2025, Geely's sales were 310,000 units, with a breakdown of 247,000 for the Geely brand, 35,000 for Lynk & Co, and 29,000 for Zeekr. Year-on-year growth rates were 29.4%, 7.3%, and 6.8%, respectively. The Galaxy model saw a remarkable year-on-year increase of 76.3% with sales of 133,000 units [7]. - The export volume in November was 42,000 units, reflecting a year-on-year increase of 22.2% [7]. New Energy Vehicles - In November, new energy vehicle sales reached 188,000 units, marking a year-on-year increase of 53.4% and accounting for 60.5% of total sales, which is an increase of 11.5 percentage points year-on-year [7]. Product Strategy - Geely plans to launch 10 new energy models in 2025, including 5 new models and several facelifts under the Geely brand. The Zeekr brand will introduce the Zeekr 007 GT and Zeekr 9X, while Lynk & Co will launch the Lynk 900 EM-P [7]. - The company is fully embracing smart technology, with a significant increase in the adoption rate of intelligent driving features across its new and updated models [7]. Financial Outlook - The expected net profit for 2025 is projected to be 17 billion yuan, with a corresponding price-to-earnings ratio of 9.2 times, indicating a strong outlook for profitability [7].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6][8]. Core Insights - In Q3 2025, the company achieved sales of 93,000 vehicles, a year-on-year decrease of 39.0%, with revenue of 27.36 billion yuan, down 36.2% year-on-year. The vehicle gross margin was 15.5%, a decline of 5.4 percentage points year-on-year. Despite short-term impacts from the MEGA recall, the company's product advantages and brand design remain strong, with a clear future model plan and ongoing optimization of direct sales channels. The "dual-energy strategy" is expected to further enhance the company's competitive edge, indicating significant future sales potential [2][4][6]. Summary by Relevant Sections Sales and Revenue Performance - In Q3 2025, the company sold 93,000 vehicles, with an average selling price of approximately 278,000 yuan. The sales volume decreased by 39.0% year-on-year and 16.1% quarter-on-quarter. The revenue for Q3 2025 was 27.36 billion yuan, with vehicle sales revenue at 25.87 billion yuan, reflecting a year-on-year decline of 37.4% [6][8]. Profitability Metrics - The company reported a net loss attributable to shareholders of 620 million yuan in Q3 2025, compared to a profit in the previous year. The adjusted net profit (Non-GAAP) was a loss of 360 million yuan. The gross margin for Q3 was 16.3%, with a vehicle gross margin of 15.5%, primarily impacted by the MEGA recall costs [4][6]. Future Outlook - The company expects Q4 2025 deliveries to be between 100,000 and 110,000 vehicles, a year-on-year decline of 30.7% to 37.0%. The projected revenue for Q4 is between 26.5 billion and 29.2 billion yuan, down 34.2% to 40.1% year-on-year. For the full year 2025, the expected delivery volume is between 397,000 and 407,000 vehicles, a decrease of 20.7% to 18.7% year-on-year [6][8]. Strategic Developments - The company is enhancing its dual-energy vehicle lineup and expanding its direct sales network, with 551 retail centers across 157 cities as of October 2025. The company has also opened its first overseas retail center in Tashkent, Uzbekistan, selling models such as the L9, L7, and L6 [6][8].

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - In November 2025, the company achieved sales of 33,181 units, representing a year-on-year decline of 31.9% but a month-on-month increase of 4.5%. Cumulatively, sales from January to November reached 362,000 units, down 18.1% year-on-year. The forecast for December sales is between 35,000 and 45,000 units, indicating a year-on-year decline of 40.1% to 23.0% but a month-on-month increase of 5.6% to 35.8% [2][4][7]. - The company is expected to enhance its product competitiveness with the upcoming L series model upgrades and the launch of the pure electric SUV i9, alongside its expansion into overseas markets, which could significantly increase sales potential [7]. - The company's "Dual Energy Strategy" is progressing well, with over 10,000 supercharging stations nationwide. As of the end of November 2025, there were 3,614 supercharging stations and 20,027 charging piles, nearing the target of 4,000 supercharging stations by year-end [7]. - The company is continuously improving its intelligent driving technology, with the OTA 8.1 update scheduled for early December, enhancing user experience through new features [7]. - The product matrix is expanding with the introduction of multiple models, including four range-extended electric SUVs and two high-voltage pure electric SUVs, which is expected to further boost sales [7]. - The company has established 544 retail centers across 157 cities and is expanding its presence in international markets, with the first overseas retail center opening in Uzbekistan [7]. - The company is projected to achieve net profits of 1.21 billion, 5.69 billion, and 8.48 billion yuan for the years 2025 to 2027, with corresponding PE ratios of 112.3X, 23.9X, and 16.0X [7].